Breaking Finance News

ValuEngine downgraded Uniqure NV (NASDAQ:QURE) to Strong Sell in a report released today.

ValuEngine has downgraded Uniqure NV (NASDAQ:QURE) to Strong Sell in a report released on 6/02/2017.

Yesterday Uniqure NV (NASDAQ:QURE) traded 27.11% higher at $5.48. The company’s 50-day moving average is $9.85 and its 200-day moving average is $7.25. The last stock close price is down 165.79% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 9,934,411 shares of the stock were exchanged, up from an average trading volume of 431,086

See Chart Below


Uniqure NV has a 52 week low of $4.72 and a 52 week high of $19.34 The company’s market cap is currently $0.

More About Uniqure NV (NASDAQ:QURE)

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company's product candidates within the Core Program include AMT-060 for Hemophilia B, AMT-130 for Huntington's disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.